Medical underperforms in Vickers' good first half:
This article was originally published in Clinica
Executive Summary
UK automotive and defence group Vickers has reported turnover of £501 million ($777 million) for the first half of the year, up 52% compared with 1994. After-tax profit improved to £18.2 million compared with £11.9 million. Contrary to the overall picture, Vickers' medical division "continues to disappoint", the company says. North America is singled out as a particularly difficult market, but Vickers maintains that major export opportunities that are being pursued should help offset the disappointment of the first half.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.